Needham analyst Alan Carr maintained a Buy rating on Nabriva (NBRV) yesterday and set a price target of $10. The company’s shares closed yesterday at $2.17.
According to TipRanks.com, Carr is a 4-star analyst with an average return of 4.6% and a 43.6% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Nabriva has an analyst consensus of Moderate Buy, with a price target consensus of $9.63, representing a 343.8% upside. In a report released yesterday, Northland Securities also assigned a Buy rating to the stock with a $12.50 price target.
See today’s analyst top recommended stocks >>
Based on Nabriva’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $30.83 million. In comparison, last year the company had a GAAP net loss of $13.34 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.